Last reviewed · How we verify
URSO Forte
At a glance
| Generic name | URSO Forte |
|---|---|
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia (NA)
- Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response (NA)
- PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer (PHASE2)
- Ursodiol Tablets 500 mg Under Fasting Conditions (PHASE1)
- Ursodiol 500 mg Tablets Under Fed Conditions (PHASE1)
- Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC) (PHASE2)
- C. Difficile and Ursodiol (PHASE4)
- Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- URSO Forte CI brief — competitive landscape report
- URSO Forte updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI